Genoa Ventures

Alida Biosciences is a biotechnology company based in San Diego, California, founded in 2020. The company focuses on developing RNA analysis tools aimed at enhancing human health. By innovating in RNA biology, Alida Biosciences seeks to advance drug discovery and therapeutic development, thereby facilitating improved medical treatments and diagnostic assays for patients.

Aqtual is a biotechnology diagnostics platform focused on healthcare solutions for chronic diseases, particularly in cancer treatment. The company has developed an innovative analytical platform that captures molecular signals from circulating deoxyribonucleic acid. This technology enhances the sensitivity, specificity, and timing of diagnostics, facilitating improved disease management. By providing personalized treatment options for cancer patients, Aqtual aims to advance the field of medical diagnostics and improve patient outcomes.

BRAINBox Solutions, Inc. is a medical technology company based in Richmond, Virginia, that specializes in developing tests for diagnosing and prognosticating mild traumatic brain injury (TBI). Founded in 2002, the company employs a multi-modality approach that integrates blood biomarker panels, neurocognitive assessments, and point-of-care instruments to deliver objective evidence of TBI and predict patient recovery outcomes. Its innovative platform combines injury-related blood protein biomarkers with computerized neurological evaluations, allowing healthcare providers to enhance diagnostic accuracy and improve patient care.

BrightSpec is a company based in Charlottesville, Virginia, specializing in innovative laboratory services and technology for analytical chemistry. It is known for its Fourier transform molecular rotational resonance (FT-MRR) platform, developed from research at the University of Virginia. This technology enables comprehensive characterization of molecules, offering sensitivity to distinguish between stereoisomers and isotopes. BrightSpec's products are particularly valuable in industries such as manufacturing process control, quality control, environmental monitoring, and formulation research. The FT-MRR platform enhances the analysis of complex mixtures without the need for chromatography, thereby improving efficiency for chemical manufacturers. By leveraging quantum theory, BrightSpec aims to revolutionize the connection between artificial intelligence and sample analytics, providing immediate results to its customers.

ZwitterCo specializes in advanced membrane solutions for the treatment of highly impaired wastewater, focusing on the development of reverse osmosis and nanofiltration technologies. These innovations enable the effective reuse and recycling of water resources by addressing challenges such as fouling and chemical demands. ZwitterCo's membranes are designed to treat historically unfilterable streams, allowing customers to transform waste into a valuable resource. With features such as chlorine tolerance and resistance to irreversible fouling, the company's technology supports steady performance and durability, making wastewater treatment economically viable for industrial applications.

Bond Pet Foods is a Boulder, Colorado-based company that specializes in creating sustainable pet food products using biotechnology. Founded in 2015, the company develops meat proteins derived from animal cells without the need for animal slaughter, and utilizes fermentation processes similar to those found in craft brewing. The proteins are cultivated in fermentation tanks and are supplemented with a nutrient-rich broth containing vitamins, sugars, and minerals, ensuring they meet the nutritional needs of companion animals. By offering all-natural and animal-free alternatives, Bond Pet Foods aims to provide environmentally friendly options for pet owners while supplying its innovative ingredients to pet food manufacturers for incorporation into their recipes and product lines.

Codetta Bio is a life sciences company that has developed a novel multi-omic analysis platform utilizing digital spatial polymerase chain reaction (dsPCR) and digital spatial immuno polymerase chain reaction (dsIPCR). This integrated platform combines reagents, hardware, and software to facilitate multiplexed liquid biopsy and the analysis of isolated DNA, RNA, and proteins. By offering a quantitative and efficient solution for biomarker measurement, Codetta Bio aims to help researchers understand the complex interplay of genetic, environmental, lifestyle, and clinical factors affecting individual health. The platform's capabilities allow for simultaneous detection of multiple analytes, enabling more effective analysis of viral and bacterial targets, mutations, and gene and protein expression. Ultimately, Codetta Bio seeks to accelerate the development of next-generation therapies, thereby enhancing patient care and quality of life.

Epitel is a digital health company focused on developing a wearable, wireless EEG monitoring platform aimed at improving seizure detection. The company offers a brain health monitoring device that accurately identifies abnormal brain activities using a proprietary cloud-based wearable sensor system combined with advanced artificial intelligence technologies. This innovative approach provides accessible, affordable, and reliable electrographic seizure detection, allowing physicians, caregivers, and patients with neurological disorders to gain valuable insights into brain health. By enhancing the quality of life and care for individuals affected by these conditions, Epitel strives to make significant contributions to the field of digital health.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.

SimBioSys is focused on advancing cancer care through its innovative Computational Microscope, which combines cutting-edge simulation techniques with extensive experimental datasets. This technology allows researchers to examine the cancer microenvironment, gaining insights into tumor behavior, cell phenotypes, and interactions with surrounding tissues. By transforming comprehensive diagnostic datasets into personalized virtual tumors, SimBioSys enhances decision-making for healthcare providers and improves patient experiences in cancer treatment. Ultimately, the platform aims to facilitate a deeper understanding of cancer dynamics, enabling more effective and tailored therapeutic approaches.

InterVenn is a life science company focused on glycoproteomics, the study of glycosylated proteins that play a crucial role in protein function. The company's pioneering AI-powered platform aims to decode the glycoproteome, which contains vital information about human biology, thereby enhancing patient outcomes. InterVenn's technology facilitates the identification, quantification, and classification of glycoproteomic signals found in blood and tissue, enabling early detection and diagnosis of cancers, particularly ovarian cancer. This platform not only supports clinical applications such as disease screening and diagnostics but also offers valuable insights for pharmaceutical partners involved in research and development. Founded by notable scientists, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn is positioned to advance personalized, predictive, and preventative healthcare solutions.

Stemson Therapeutics, LLC is a cell therapy company based in La Jolla, California, focused on addressing hair loss by restoring natural hair through innovative treatments. Founded in 2018, the company utilizes a proprietary process that employs induced pluripotent stem cells (iPSC) to generate new dermal papilla, the essential cells needed for hair follicle regeneration. Its flagship product, the Stemson solution, combines engineered cells with a unique tissue engineering approach to create a sustainable supply of new hair follicles for patients. By providing effective solutions for individuals experiencing hair loss, Stemson Therapeutics aims to alleviate the emotional and social challenges associated with this condition.

BloodQ develops an analytical platform designed for cancer drug treatment. Its platform captures disease molecular signals in circulating DNA to improve sensitivity, specificity, and timing in diagnostic and disease management, thereby providing patients personalized cancer treatment.

Attune Neurosciences is a medical device company that focuses on enhancing human health and performance through the development of clinically proven, non-invasive neurostimulation products. The company primarily targets sleep- and wake-related conditions, aiming to help patients manage symptoms associated with central nervous system disorders. By modulating the activity of brain structures, Attune's products are designed to support not only individual patients but also government and industrial applications.

BRAINBox Solutions, Inc. is a medical technology company based in Richmond, Virginia, that specializes in developing tests for diagnosing and prognosticating mild traumatic brain injury (TBI). Founded in 2002, the company employs a multi-modality approach that integrates blood biomarker panels, neurocognitive assessments, and point-of-care instruments to deliver objective evidence of TBI and predict patient recovery outcomes. Its innovative platform combines injury-related blood protein biomarkers with computerized neurological evaluations, allowing healthcare providers to enhance diagnostic accuracy and improve patient care.

InterVenn is a life science company focused on glycoproteomics, the study of glycosylated proteins that play a crucial role in protein function. The company's pioneering AI-powered platform aims to decode the glycoproteome, which contains vital information about human biology, thereby enhancing patient outcomes. InterVenn's technology facilitates the identification, quantification, and classification of glycoproteomic signals found in blood and tissue, enabling early detection and diagnosis of cancers, particularly ovarian cancer. This platform not only supports clinical applications such as disease screening and diagnostics but also offers valuable insights for pharmaceutical partners involved in research and development. Founded by notable scientists, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn is positioned to advance personalized, predictive, and preventative healthcare solutions.

IonPath, Inc., based in Menlo Park, California, specializes in multiplexed ion beam imaging services for pathology. Founded in 2014, the company has developed advanced ion beam imaging technology that allows for detailed analysis of tissue biopsies, including fresh, frozen, and formalin-fixed paraffin-embedded (FFPE) samples. This technology goes beyond traditional light microscopy, providing a comprehensive understanding of the tissue microenvironment through highly multiplexed quantitative single-cell analysis. By enabling healthcare providers to obtain actionable insights, IonPath's services facilitate accurate cancer diagnoses and contribute to advancements in human health.

Tropic Biosciences specializes in developing high-performing commercial varieties of tropical crops, utilizing advanced non-GMO gene editing techniques. The company focuses on promoting cultivation efficiencies to address the increasing global food demand while enhancing grower wellbeing and consumer health. By significantly accelerating the breeding process, Tropic Biosciences aims to deliver genetic improvements that empower local farming communities to produce organic crops. Their commitment to sustainable agricultural practices reflects a broader goal of improving environmental outcomes.

Intabio, Inc. is a biopharmaceutical analytics company founded in 2015 and based in Newark, California. The company specializes in developing innovative analytical solutions designed to enhance the efficiency of biopharmaceutical development and manufacturing. Intabio's key product, the Blaze system, is a bench-top instrument that utilizes a microfluidic chip and reagent kit to perform separation, quantitation, and molecular mass identity analysis. This system is particularly valuable for identifying unwanted structural modifications in intact biotherapeutic proteins. Intabio also offers a microfluidic platform that enables real-time characterization of protein isoforms, aiding in the identification of specific modifications. By providing early product quality characterization, Intabio's technologies significantly improve throughput and reduce costs compared to traditional methods, facilitating the comprehensive analysis of antibody and protein biopharmaceuticals in development.

InterVenn is a life science company focused on glycoproteomics, the study of glycosylated proteins that play a crucial role in protein function. The company's pioneering AI-powered platform aims to decode the glycoproteome, which contains vital information about human biology, thereby enhancing patient outcomes. InterVenn's technology facilitates the identification, quantification, and classification of glycoproteomic signals found in blood and tissue, enabling early detection and diagnosis of cancers, particularly ovarian cancer. This platform not only supports clinical applications such as disease screening and diagnostics but also offers valuable insights for pharmaceutical partners involved in research and development. Founded by notable scientists, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn is positioned to advance personalized, predictive, and preventative healthcare solutions.

Intabio, Inc. is a biopharmaceutical analytics company founded in 2015 and based in Newark, California. The company specializes in developing innovative analytical solutions designed to enhance the efficiency of biopharmaceutical development and manufacturing. Intabio's key product, the Blaze system, is a bench-top instrument that utilizes a microfluidic chip and reagent kit to perform separation, quantitation, and molecular mass identity analysis. This system is particularly valuable for identifying unwanted structural modifications in intact biotherapeutic proteins. Intabio also offers a microfluidic platform that enables real-time characterization of protein isoforms, aiding in the identification of specific modifications. By providing early product quality characterization, Intabio's technologies significantly improve throughput and reduce costs compared to traditional methods, facilitating the comprehensive analysis of antibody and protein biopharmaceuticals in development.

IonPath, Inc., based in Menlo Park, California, specializes in multiplexed ion beam imaging services for pathology. Founded in 2014, the company has developed advanced ion beam imaging technology that allows for detailed analysis of tissue biopsies, including fresh, frozen, and formalin-fixed paraffin-embedded (FFPE) samples. This technology goes beyond traditional light microscopy, providing a comprehensive understanding of the tissue microenvironment through highly multiplexed quantitative single-cell analysis. By enabling healthcare providers to obtain actionable insights, IonPath's services facilitate accurate cancer diagnoses and contribute to advancements in human health.

NanoCellect Biomedical, Inc. is a company based in San Diego, California, specializing in the development of innovative flow cytometry and cell sorting technologies for life science researchers. Founded in 2009, it offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to enable efficient cell sorting while minimizing biohazard risks and shear stress associated with traditional methods. The company’s portfolio includes affordable and compact microfluidic-based instruments and consumables that facilitate cellular analysis essential for drug discovery, single cell-omics, cloning, antibody discovery, and basic research. By simplifying the process of analyzing and sorting distinct cell populations, NanoCellect Biomedical supports biomedical scientists in advancing their research and improving personalized medicine.

Intabio, Inc. is a biopharmaceutical analytics company founded in 2015 and based in Newark, California. The company specializes in developing innovative analytical solutions designed to enhance the efficiency of biopharmaceutical development and manufacturing. Intabio's key product, the Blaze system, is a bench-top instrument that utilizes a microfluidic chip and reagent kit to perform separation, quantitation, and molecular mass identity analysis. This system is particularly valuable for identifying unwanted structural modifications in intact biotherapeutic proteins. Intabio also offers a microfluidic platform that enables real-time characterization of protein isoforms, aiding in the identification of specific modifications. By providing early product quality characterization, Intabio's technologies significantly improve throughput and reduce costs compared to traditional methods, facilitating the comprehensive analysis of antibody and protein biopharmaceuticals in development.

Akadeum Life Sciences, Inc. is a life sciences company based in Ann Arbor, Michigan, founded in 2014. The company specializes in manufacturing microbubble cell separation products designed to facilitate the removal of target cells from biological samples. Its product line includes T cell and B cell isolation kits for both human and mouse cells, as well as products for red blood cell depletion. Akadeum utilizes buoyancy-activated cell sorting technology, employing microscopic microbubbles that capture target cells and float them to the surface for efficient removal. This innovative approach enhances the efficiency of downstream testing and analysis for medical practitioners. The company's products are available for purchase online, and it maintains a strategic partnership with Agilent Technologies.

Adarza BioSystems is an early-stage medical diagnostics company based in St. Louis, Missouri, founded in 2008. The company specializes in developing a rapid and label-free biological assay platform that measures clinical and point-of-care samples. This innovative platform employs diagnostic arrayed imaging reflectometry (AIR) to enable the simultaneous detection of hundreds of analytes from a single drop of fluid, allowing healthcare professionals to conduct sophisticated tests with high sensitivity and specificity. By significantly reducing the time required for testing, Adarza BioSystems aims to enhance diagnostic capabilities in various healthcare settings.

Synthomics, Inc. specializes in oligonucleotide synthesis solutions, providing advanced RNA and DNA synthesizers that enhance the efficiency and quality of oligonucleotide production. Based in Menlo Park, California, the company develops products for diverse applications, including research, diagnostics, pharmaceuticals, and agriculture. Their innovative synthesizer can accommodate up to 1,536 unique oligonucleotides simultaneously, significantly surpassing the industry standard of 96. This capability not only reduces reagent consumption but also lowers costs and improves turnaround times. Synthomics' flagship "Green Machine" further streamlines DNA synthesis, achieving cost reductions of 20 to 100 times while minimizing waste and enhancing overall quality. Their solutions support critical processes such as next generation sequencing, gene synthesis, gene editing, and PCR, making significant contributions to life sciences innovation.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, that specializes in cellular engineering and genome editing solutions using CRISPR technology. Incorporated in 2011, the company has developed a CRISPR-Cas gene editing platform that allows precise modifications to DNA, which is applicable across various fields including human and animal therapeutics, agricultural biotechnology, and industrial biotech. Caribou's innovative approach aims to create transformative therapies, particularly in the development of allogeneic CAR-T and CAR-NK cell therapies, targeting serious diseases. The company focuses on advancing its pipeline of next-generation genome-edited cell therapies while also contributing to basic and applied biological research.

Pivot Bio is a biotechnology company founded in 2010 and based in Emeryville, California, that focuses on enhancing crop nutrition through the use of engineered microbes. The company leverages its deep understanding of the plant microbiome, employing engineering principles and data science to map microbial dynamics and develop beneficial traits. Pivot Bio's proprietary ON Technology utilizes naturally occurring microbes to provide crops with essential nutrients, particularly nitrogen, which is crucial for growth. This innovative approach aims to replace synthetic nitrogen fertilizers, thereby reducing the environmental impact associated with conventional farming practices. By enhancing crops' ability to capture and metabolize atmospheric nitrogen, Pivot Bio seeks to lower farming costs, improve crop yields, and contribute to a sustainable agricultural future that benefits both the planet and food supply.

IonPath, Inc., based in Menlo Park, California, specializes in multiplexed ion beam imaging services for pathology. Founded in 2014, the company has developed advanced ion beam imaging technology that allows for detailed analysis of tissue biopsies, including fresh, frozen, and formalin-fixed paraffin-embedded (FFPE) samples. This technology goes beyond traditional light microscopy, providing a comprehensive understanding of the tissue microenvironment through highly multiplexed quantitative single-cell analysis. By enabling healthcare providers to obtain actionable insights, IonPath's services facilitate accurate cancer diagnoses and contribute to advancements in human health.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, that specializes in cellular engineering and genome editing solutions using CRISPR technology. Incorporated in 2011, the company has developed a CRISPR-Cas gene editing platform that allows precise modifications to DNA, which is applicable across various fields including human and animal therapeutics, agricultural biotechnology, and industrial biotech. Caribou's innovative approach aims to create transformative therapies, particularly in the development of allogeneic CAR-T and CAR-NK cell therapies, targeting serious diseases. The company focuses on advancing its pipeline of next-generation genome-edited cell therapies while also contributing to basic and applied biological research.

Zephyrus Biosciences, Inc. is a life science research tools company based in Berkeley, California, founded in 2013. The company specializes in the development and commercialization of innovative research tools that facilitate protein analysis at the single-cell level. Its flagship product, the scWestern System, allows for western blotting on individual cells, a significant advancement in the field of single-cell analysis. This system employs microfluidics technology to isolate single cells in micro-wells, lysing them and performing SDS-PAGE separation on each lysate. Researchers utilize Zephyrus's tools to explore critical areas such as cancer biology, stem cell research, neurology, and broader human disease studies, ultimately contributing to advancements in diagnostics and therapeutics. As of March 2016, Zephyrus operates as a subsidiary of Bio-Techne Corp.

Zymergen, Inc. is a biotechnology company that focuses on researching, developing, and manufacturing microbes for various industries, including agriculture, chemicals, materials, pharmaceuticals, electronics, and personal care. Founded in 2013 and headquartered in Emeryville, California, Zymergen employs a platform that integrates automation, machine learning, and genomics to enhance the efficiency of microbial strain optimization and production processes. This technology enables the company to improve existing manufacturing strains and facilitates the development of new products by engineering novel molecules from microbes. With additional offices in Boise, Idaho; Medford, Massachusetts; Seattle, Washington; and Tokyo, Japan, Zymergen aims to partner with nature to create innovative materials and products that deliver significant value across multiple sectors.